TREATMENT OF NEUROPATHIC PAIN WITH N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONISTS

• US 20130123295A1
• Filed: 10/05/2012
• Published: 05/16/2013
• Est. Priority Date: 06/07/2001
• Status: Abandoned Application

• Current Assignee: Analgesic Neuropharmaceuticals, Inc.
• Original Assignee: Analgesic Neuropharmaceuticals, LLC
• Inventors: Sang, Christine N.
• Application Number:
  US13/646,244
• Publication Number:
  US 20130123295A1
• Time in Patent Office: Days
• US Class Current: 514/289
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Central neuropathic pain is treated with an analgesic composition that consists essentially of an N-methyl-D-aspartate (NMDA) receptor antagonist. In one embodiment, the invention includes chronic administration of the (NMDA) receptor antagonist. In another embodiment, the invention is use of an NMDA receptor antagonist or component thereof for the manufacture of a medicament than includes an analgesic component that consists essentially of an NMDA receptor antagonist for the chronic treatment of central neuropathic pain.

Claims

1-32. -32. (canceled)

33. A method for treating spinal cord injury in a subject in need thereof, comprising administering to the subject a selected therapy established as preferred by a method comprising steps of:

administering to a set of subjects a plurality of distinct therapeutic regimens that all administer the same active ingredient or ingredients;

collecting input from subjects in the set regarding the subjects'"'"' preference between or among administered therapeutic regimens;

determining that one of the therapeutic regimens is statistically selected as preferred by subjects in the set over at least one other of the therapeutic regimens, and therefore is the selected therapy.

34. The method of claim 33, wherein the selected therapy involves administration of two or more active ingredients.

35. The method of claim 33, wherein the subject being administered the selected therapy is a human patient.

36. The method of claim 33, wherein the set of subjects undergo evaluation at least once weekly during the sequence of different treatments.

37. The method of claim 36, wherein the set of subjects undergo evaluation at least twice weekly during the sequence of different treatments.

38. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of global pain intensity.

39. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of Global Pain Intensity.

40. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of global pain relief.

41. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of Global Pain Relief.

42. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of pain intensity of individual pain descriptors selected from burning pain, aching pain, tingling pain, cold pain, brief lancinating pain, deep stabbing pain, constricting pain, and touch-evoked pain.

43. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of areas of evoked pain.

44. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of quality of life.

45. The method of claim 33, wherein the step of collecting input from subjects in the set comprises collecting subjects'"'"' assessment of patient satisfaction.

46. The method of claim 33, wherein the touch-evoked pain is allodynia.